BioCentury
ARTICLE | Clinical News

Alexo reports Phase I data for its CD47 inhibitor

December 1, 2017 10:06 PM UTC

Alexo Therapeutics Ltd. (Dublin, Ireland) reported data from 17 patients with advanced solid tumors and lymphoma in the single-agent portion of an open-label, dose-escalation Phase I trial showing that 0.3-30 mg/kg doses of ALX148 monotherapy were well tolerated. There was 1 serious treatment-related adverse event of neutropenia plus infection at the 3 mg/kg dose. Evaluation of the highest dose is ongoing. Data were presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Md.

The second portion of the trial will evaluate ALX148 in combination with Keytruda pembrolizumab, Herceptin trastuzumab and Rituxan rituximab. The trial will enroll about 142 patients. The primary endpoint is dose-limiting toxicities (DLTs)...